US92243A2006 - Common Stock
VAXART INC
NASDAQ:VXRT (5/3/2024, 7:25:53 PM)
After market: 0.7401 +0.01 (+1.54%)0.7289
-0.02 (-2.68%)
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 164 full-time employees. Its programs include tablet vaccine candidates designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine candidate for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine candidate that protect against norovirus GI and norovirus GII, by targeting the norovirus GI.1 Norwalk strain and the norovirus GII.4 Sydney strain; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer.
VAXART INC
170 Harbor Way, Suite 300
South San Francisco CALIFORNIA 94080
P: 16505503500
CEO: Andrei Floroiu
Employees: 164
Website: https://vaxart.com/
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody...
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief...
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the...
VXRT stock results show that Vaxart beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart (NASDAQ:VXRT) just reported results for the fourth quarter of 2023.Vaxar...
Here you can normally see the latest stock twits on VXRT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: